[4-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone → (R)-[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl][4-(4-methyl-1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[CH3:1][C@H:2]1[CH2:6][S:5](=[O:8])(=[O:7])[NH:4][CH2:3]1.[CH:9]1([C:12]2[CH:13]=[C:14]([CH3:33])[C:15]([N:18]3[CH2:23][CH2:22][N:21]([C:24]([C:26]4[CH:31]=[CH:30][C:29](I)=[CH:28][CH:27]=4)=[O:25])[CH2:20][CH2:19]3)=[N:16][CH:17]=2)[CH2:11][CH2:10]1>>[CH:9]1([C:12]2[CH:13]=[C:14]([CH3:33])[C:15]([N:18]3[CH2:23][CH2:22][N:21]([C:24]([C:26]4[CH:31]=[CH:30][C:29]([N:4]5[CH2:3][C@@H:2]([CH3:1])[CH2:6][S:5]5(=[O:8])=[O:7])=[CH:28][CH:27]=4)=[O:25])[CH2:20][CH2:19]3)=[N:16][CH:17]=2)[CH2:10][CH2:11]1참가 물질
3
실험 절차
Using (R)-4-methylisothiazolidine 1,1-dioxide (91 mg) described in Preparation Example 7 and [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (200 mg) described in Preparation Example 117 and by the reaction and treatment in the same manner as in Example 1, the title compound (70 mg) was obtained.